|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
P<i>ostmortem</i> DLPFC expression data analysis showed decreased expression levels of NURR1 and ERR1 in patients with SCZ.
|
31811028 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate for the first time that NR4A2 is pro-oncogenic in GBM and thus a potential druggable target for patients with tumors expressing this receptor.
|
31754919 |
2020 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
NR4A2 knockdown and DIM-C-pPhCl inhibited GBM cell and tumor growth, induced apoptosis and inhibited migration and invasion of GBM cells.
|
31754919 |
2020 |
|
Memory impairment
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we show that activation of Nr4a2 by 1,1-bis(3'-Indolyl)-1-(p-chlorophenyl) methane (C-DIM12), enhances long-term spatial memory in young mice and rescues memory deficits in aged mice.
|
31732218 |
2020 |
|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia.
|
31746417 |
2020 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, our bis-indole-derived NR4A2 antagonists represent a novel class of anti-cancer agents with potential future clinical applications for treating GBM.
|
31754919 |
2020 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, our bis-indole-derived NR4A2 antagonists represent a novel class of anti-cancer agents with potential future clinical applications for treating GBM.
|
31754919 |
2020 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings should stimulate future studies to probe the ligandability and druggability of Nurr1 for both endogenous and synthetic ligands, which could lead to new therapeutics for Nurr1-related diseases, including Parkinson's disease and schizophrenia.
|
30416039 |
2019 |
|
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
NURR1 alterations have been linked to DA-associated brain disorders, such as Parkinson's disease and schizophrenia.
|
31455763 |
2019 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In parallel, NURR1 has been also linked to dopamine-associated brain disorders, such as Parkinson's disease (PD) and schizophrenia, since it is involved in the development and in the maintenance of midbrain dopaminergic neurons (mDA).
|
31574937 |
2019 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
NURR1 alterations have been linked to DA-associated brain disorders, such as Parkinson's disease and schizophrenia.
|
31455763 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Bis-indole derivatives including 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane (DIM-C-pPhCl) and substituted quinolines such as chloroquine (CQ) and amodiaquine (AQ) are nuclear receptor 4A2 (NR4A2, Nurr1) ligands, and they exhibit anti-inflammatory activities in mouse and rat models of Parkinson's disease, respectively.
|
31102570 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Altogether, the enhancement of tyrosine hydroxylase in naïve dopaminergic cells and the protective effects in a cellular model of Parkinson's disease suggest that full-length Nurr1 fusion protein may contribute to the development of a novel concept of protein-based therapy.
|
30121937 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In parallel, NURR1 has been also linked to dopamine-associated brain disorders, such as Parkinson's disease (PD) and schizophrenia, since it is involved in the development and in the maintenance of midbrain dopaminergic neurons (mDA).
|
31574937 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings should stimulate future studies to probe the ligandability and druggability of Nurr1 for both endogenous and synthetic ligands, which could lead to new therapeutics for Nurr1-related diseases, including Parkinson's disease and schizophrenia.
|
30416039 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The orphan nuclear receptor Nurr1 (also known as NR4A2) is critical for the development and maintenance of midbrain dopaminergic neurons, and is associated with Parkinson's disease.
|
30515963 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study suggests that ABZ exerts a neuroprotective effect in a rotenone-induced PD model associated with HIF-1α and Nurr1 activation and thus may be a viable candidate for treating PD.
|
31408200 |
2019 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model.
|
30949504 |
2019 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Since decrease in Nurr1 function either due to diminished expression or rare mutation is associated with Parkinson's disease (PD), upregulation of Nurr1 may be beneficial for PD.
|
31127527 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the protective effects of CP on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) induced PD in mice and explored the underlying mechanisms of action, focusing on Nurr1.
|
31772707 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, peripheral Nurr1 was significantly decreased in PD compared with HC (56%, p < 0.001) and NDC (58%, p < 0.001).
|
30817108 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings suggest avenues for developing synthetic Nurr1 ligands to ameliorate the symptoms and progression of Parkinson's disease.
|
30853418 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
|
30773432 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The nuclear receptor Nurr1 (NR4A2) has been identified as a potential target for the treatment of Parkinson's disease.
|
30582418 |
2019 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ectopic NR4A2 expression has been reported to be related with familial Parkinson disease, and through dual luciferase we found that NR4A2 is a target gene of microRNA-183 (miR-183).
|
30191980 |
2019 |